Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Pozycja w akcjach #39175
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Cena akcji
$0.378
Ostatnia synchronizacja: 2024-05-24
Kapitalizacja rynkowa
$618.41K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel NeuBase Therapeutics, Inc. (NBSE)

Kategoria

Historia ceny akcji dla NeuBase Therapeutics, Inc. (NBSE)
Najwyższa cena zamknięcia: $0.39 dnia 2024-05-01

Najniższa cena zamknięcia: $733.33 dnia 2004-05-01
Historia cen akcji firmy NeuBase Therapeutics, Inc. od 2004 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2024 -49.90%
2023 -81.22%
2022 -92.72%
2021 -64.02%
2020 7.86%
2019 205.09%
2018 -92.38%
2017 -19.09%
2016 -60.75%
2015 75.31%
2014 6.31%
2013 49.44%
2012 167.16%
2011 169.72%
2010 -59.63%
2009 129.24%
2008 14.29%
2007 -48.15%
2006 -74.29%
2005 -15.32%
2004 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$517.18 32.51%
US
$857.76 31.47%
NL
$728.05 6.60%
CH
$1.07K -6.40%
KR
$254.79 12.56%
BE